The purpose of contemporary study was to project GNP by using of two step desolvation method. Biodegradable hydrophilic gelatin nanoparticles used as a delivery system of anti-inflammatory lornoxicam after gel formulation using each of hydroxyl propyl methyl cellulose (HPMC) and carbopol as gelling agent. The size and shape of the nanoparticles were examined by optical microscope and transmission electron microscopy, particles with a mean diameter of 240.6 nm and 0.1 poly dispersibility index PDI were produced and the percentage of entrapment efficiency was found to be 87.1%. The optimum amount of LOR loading was obtained. Four formulas were prepared F1, F2 are slandered drug gel and F3 and F4 are GNP-LOR gel. Permeation of drug throug...
Present effort intends to improve the performance of gelatin based casted-films for controlled deliv...
The aim of the present work was to develop controlled release matrix tablets of Lornoxicam using pol...
Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dos...
Solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and nanoemulsion (NE) of lornox...
In side this task a kind attempt has been made to formulate and evaluate Microspheres of the drug Ni...
© 2016, Controlled Release Society. Proniosomes are the new generation provesicular drug delivery sy...
The aim of this study was to prepare ganciclovir (GCV)-loaded cross-linked gelatin microspheres by s...
In this research a novel drug polymer was prepared. The gelatin as a natural polymer has been used ...
This paper describes the use of oxidised dextran as cross-linker for the preparation of gelatin mic...
The current research work was an attempt to develop and evaluate matrix-type transdermal therapeutic...
Aim of the present study was to develop site-specific drug delivery system of lornoxicam for the tre...
<p>Gelatine nanoparticles (GNPs) are biodegradable and biocompatible drug delivery systems with exce...
Objective: Transdermal drug delivery systems deliver the drug through the skin at controlled rate to...
A chronic illness has been mostly accomplished by delivery of drugs to patients using various pharma...
Purpose: To formulate double-layer tablets of lornoxicam (LRX) prepared by direct compression method...
Present effort intends to improve the performance of gelatin based casted-films for controlled deliv...
The aim of the present work was to develop controlled release matrix tablets of Lornoxicam using pol...
Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dos...
Solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and nanoemulsion (NE) of lornox...
In side this task a kind attempt has been made to formulate and evaluate Microspheres of the drug Ni...
© 2016, Controlled Release Society. Proniosomes are the new generation provesicular drug delivery sy...
The aim of this study was to prepare ganciclovir (GCV)-loaded cross-linked gelatin microspheres by s...
In this research a novel drug polymer was prepared. The gelatin as a natural polymer has been used ...
This paper describes the use of oxidised dextran as cross-linker for the preparation of gelatin mic...
The current research work was an attempt to develop and evaluate matrix-type transdermal therapeutic...
Aim of the present study was to develop site-specific drug delivery system of lornoxicam for the tre...
<p>Gelatine nanoparticles (GNPs) are biodegradable and biocompatible drug delivery systems with exce...
Objective: Transdermal drug delivery systems deliver the drug through the skin at controlled rate to...
A chronic illness has been mostly accomplished by delivery of drugs to patients using various pharma...
Purpose: To formulate double-layer tablets of lornoxicam (LRX) prepared by direct compression method...
Present effort intends to improve the performance of gelatin based casted-films for controlled deliv...
The aim of the present work was to develop controlled release matrix tablets of Lornoxicam using pol...
Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dos...